Available at Amazon, Barnes and Noble, Christian Book and fine booksellers everywhere
Join 24,285 other subscribers
Thanks to Ministry-To-Children!
February 2023 S M T W T F S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
“The most complete special needs ministry resource I’ve ever come across.”
- Our monthly Idea Share will happen today at 12 Eastern! Click the link to register. loom.ly/nXnrev0… twitter.com/i/web/status/1… 2 hours ago
- Idea Share is a time for disability ministry leaders from across the country to support and encourage each other wh… twitter.com/i/web/status/1… 2 days ago
- We recently found out that Amazon will be phasing out their Smile Program beginning on February 20th. Remember to u… twitter.com/i/web/status/1… 2 days ago
- It's nearly been 5 years since Mental Health and the Church by Dr. Stephen Grcevich was published. How has MHATC he… twitter.com/i/web/status/1… 3 days ago
- Grab your early bird pricing for #DATC2023 now through February 28th! Click here for more info:… twitter.com/i/web/status/1… 3 days ago
Honored to be in Sharecare Now’s Top Ten online influencers in children’s mental health!
Tag Archives: FDA
Patients with depression were eleven times more likely to experience significant benefit from antidepressant medication than to experience medication-related suicidal thinking or behavior, patients with OCD were thirty-four times more likely to experience benefit and patients with non-OCD anxiety were thirty-six times more likely to experience benefit. Continue reading
Few topics in child and adolescent mental health have generated as much controversy over the last decade as the debate about the safety of antidepressant medication given to kids. In 2004, the FDA issued a “black box” warning claiming that antidepressant use in children and teenagers is associated with increases in suicidal thinking and behavior, which was expanded in 2007 to include adults between the ages of 18 and 24. In my opinion, the larger controversy about antidepressant use in children and teens is not “are they safe?” but “do they work?” and if they work, what do they work for? Some of those questions were addressed here.
One of the greatest ongoing controversies in the fields of child psychiatry and pediatrics is the question of how safe SSRIs are in children, teens and young adults. The safety issue of greatest concern involves reported risks of SSRIs increasing suicidal thoughts during the first 30-60 days of treatment in persons under the age of 25.